Clinical Trial Update: Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on EXO-CD24 for preventing deterioration in patients with mild to moderate ARDS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• EXO-CD24 (EXO-CD24)

Snippet

Sponsor: Nano24med | Conditions: ARDS | Phase 2 | Status: UNKNOWN